Opportunity to advance Pfizer’s expertise and deep heritage in infectious disease
NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections.
More than 1.5 million cases of invasive fungal infections occur worldwide each year, with mortality rates as high as 30-80% across infection types
i. Fosmanogepix has a novel mechanism of action with the potential to target fungal strains resistant to standard of care therapy. As there are only three classes of antifungal medications currently available, antifungal resistance can severely limit treatment options; a potential new therapeutic class may therefore be of impo
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
Pfizer Acquires Amplyx Pharmaceuticals
Opportunity to advance Pfizer s expertise and deep heritage in infectious disease
NEW YORK Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx s lead compound, Fosmanogepix (APX001), is a novel investigational asset
Pfizer Acquires Amplyx Pharmaceuticals investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
The health sector in Spain attracts 140 million in investments
The health sector in Spain attracts 140 million in investments
Spanish investment funds and venture capital managers have avoided the impact of the pandemic and have continued to invest in the health sector. Spanish biotech companies account for more than half of the total amount raised in the financing rounds of national companies. The funds raised by biotechnology companies amount to more than $98.3 million (€80 million), half of which has been raised by Ona Therapeutics
SHARES
The health sector in Spain is taking advantage of the pandemic, increasing its potential, and giving entry to investors from other areas. Driven by the healthcare crisis, which has put value on the sector, biotechnology, life sciences, and digital therapeutics companies have continued to attract capital. Due to the volatility of the market, the sector has attracted more traditional investors and those from other fields such as tourism or re
Reneo Pharmaceuticals Raises $95M in Series B Financing finsmes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finsmes.com Daily Mail and Mail on Sunday newspapers.